subclassification ( P <.001). This was a generally healthy cohort, with a CDCI score of 0 in 88% of men, indicating no comorbid conditions recorded ( P =.415). Table 2. Baseline Patient Characteristics Baseline tumor characteristics across cT2 subclassifications
Search Results
Jenna F. Borkenhagen, Daniel Eastwood, Deepak Kilari, William A. See, Jonathan D. Van Wickle, Colleen A. Lawton, and William A. Hall
Soumyajit Roy, Paul Hoskins, Anna Tinker, Harinder Brar, Gale Bowering, and Gaurav Bahl
distribution of stage, year of diagnosis, and risk category in the treatment groups. Table 1. Patient Characteristics Some deviation from protocol-defined treatment was noted in the treatment groups ( supplemental eTable 1 ). In the chemo-PRT group, 3D
Ang Li, Qian Wu, Suhong Luo, Greg S. Warnick, Neil A. Zakai, Edward N. Libby, Brian F. Gage, David A. Garcia, Gary H. Lyman, and Kristen M. Sanfilippo
of the Declaration of Helsinki. Use of the VHA database was approved by the St. Louis Veterans Affairs Medical Center IRB. Results Cohort Descriptions Baseline patient characteristics for the derivation (SEER-Medicare) and external validation (VHA
Sarah Asad, Carlos H. Barcenas, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Ellis G. Levine, Nancy U. Lin, Beverly Moy, Joyce Niland, Antonio C. Wolff, Michael J. Hassett, and Daniel G. Stover
validation cohorts. Model performance of the final bootstrapped model was assessed in the training and validation cohorts using receiver operating characteristic (ROC) curves with area under the curve (AUC) statistics; ROC curves compare sensitivity to
George L. Jackson, Leah L. Zullig, S. Yousuf Zafar, Adam A. Powell, Diana L. Ordin, Ziad F. Gellad, David Abbott, James M. Schlosser, Janis Hersh, and Dawn Provenzale
accredited by the American College of Surgeons Commission on Cancer in 2005; an additional 8 facilities [30%] were in the process of applying for accreditation). 21 Characteristics of the 27 facilities using CCQMS reports are detailed in Table 3
Chetna Malhotra, Ling En Koh, Irene Teo, Semra Ozdemir, Isha Chaudhry, and Eric Finkelstein
% answered surveys at 6, 12, 18, and 24 months, respectively. The 134 patients excluded from the analysis were similar to those in our analytic sample (n=466) in terms of age and sex. Table 1 shows patient baseline characteristics. Table 1. Patient
Tiffany Li, Hannah C. Timmins, Terry Trinh, David Mizrahi, Michelle Harrison, Lisa G. Horvath, Peter Grimison, Michael Friedlander, Matthew C. Kiernan, Madeleine T. King, Claudia Rutherford, David Goldstein, and Susanna B. Park
Clinical Characteristics (N=406) At baseline assessment, most patients (79.3%; n=322/406) did not have neuropathy symptoms (CTCAE grade 0; Table 1 ). By midtreatment (8.9 ± 4.8 weeks from baseline), 62.2% (n=199/320) had CIPN symptoms (CTCAE grade ≥1
Yixing Jiang, Heath Mackley, Hua Cheng, and Jaffer A. Ajani
Characteristics Among the Major Phase III Studies Ajani et al. 31 showed that patients with tumors greater than 5 cm, irregardless of nodal status, had a higher colostomy rate and inferior disease-free survival. Roohipour et al. 32 showed that treatment
Christina Teng, Venkatesha, Prunella L. Blinman, and Janette L. Vardy
. All the statistical tests were performed at a 0.05 level of significance. All statistical analyses were performed in SPSS Statistics, version 26 (IBM Corp). Results Participant Characteristics The cohort comprised 233 patients with CRC
Jessica D. McDermott, Megan Eguchi, Rustain Morgan, Arya Amini, Julie A. Goddard, Evelinn A. Borrayo, and Sana D. Karam
modern era. We used updated SEER-Medicare population data to derive information on patient and tumor characteristics and treatment, payment, and healthcare use data to control for bias of different healthcare/insurance coverage. We focused our comparisons
